Insulin Price Reduction Act

Issues related to Affordable Care Act Premium Tax credits; H.R. 6833/S. 3700 - Affordable Insulin Now Act; S. 2199 - Insulin Price Reduction Act.

Client expense: Not reported · Firm income: $30,000

Government targets: SENATE

Issues related to drug pricing; issues related to Drug Pricing in H.R.5376 "Build Back Better Act"; issues related to influenza vaccines; issues related to RSV Access; issues related to routine immunization rates; general issues related to vaccines; issues related to 340B; issues related to RX to OTC switch; issues related to Pandemic Preparedness; issues related to Reconciliation; issues related to "Give Kids a Chance Act" in RACE 2.0; general issues related to HR 5376 "Build Back Better Act"; issues related to Cosmetic Reform; issues related to S.3700 and HR 6833 "Affordable Insulin Now Act"; issues related to s.2199 "Insulin Price Reduction Act"; issues related to NSURE Rule; issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); issues related to Clinical Trial Diversity; issues related to Accelerated Approval; issues related to HR 6972 "Give Kids a Chance Act of 2022"; issues related to HR 6854 "Depict Act"; issues related to Out-of-Pocket Cap; general issues related to Insulin pricing; issues related to "Improving Needed Safeguards for Users for Lifesaving Insulin Now (INSULIN) Act"; issues related to HR7667 "Food and Drug Amendments of 2022"; issues related to S.4348 "Food and Drug Administration and Landmark Advancements (FDASLA) Act; issues related to S.4293 "Pharmacy Benefit Managers Transparency Act of 2022"; and issues related to drug importation.

Client expense: $1,300,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 2199-Insulin Price Reduction Act; S.4293-Pharmacy Benefit Manager Transparency Act of 2022; S. 1388-Prescription Pricing for the People Act of 2021.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

P.L. 116-136, Coronavirus Aid, Relief, and Economic Security (CARES) Act - provisions related to infusion issues for Medicare patients, amendments to the Tax Cuts and Jobs Act (TCJA), plasma awareness, and the orphan drug tax credit; Issues related to patient access of plasma therapies; Discussions to clarify or reform the 340B program; Discussions on value-based drug contracting; Issues related to prescription drug vial sizes; Proposals related to drug pricing, including House and Senate draft bills; Discussions related to co-pay accumulators; H.R. 6000, Cures 2.0 Act - provisions related to the pharmaceutical industry; Discussions related to amending P.L. 97-414, Orphan Drug Act; Issues related to global pharmaceutical supply chain operations and manufacturing locations; HHS/FDA Safe Importation Action Plan - provisions related to the importation of prescription drugs; H.R. 482, S. 350, Newborn Screening Saves Lives Reauthorization of 2021 - provisions related to newborn screening; S. 1281, To amend the CARES Act to expand a national awareness and outreach campaign to address the importance and safety of plasma donation, and for other purposes - provisions related to plasma donation; H.R. 3468, S. 1281, Plasma Donation Awareness Act - provisions related to requiring HHS to initiate a plasma donation awareness campaign much like the one required for blood donation in P.L. 116-136 (CARES Act); H.R. 2163, S. 464, Safe Step Act - provisions related to step therapy policy; H.R. 1730, S. 670, The STAT Act - The Speeding Therapy Access Today Act of 2021 - provisions related to establishment of a Rare Disease Center of Excellence within FDA; H.R. 19, Lower Costs, More Cures Act of 2021 - provisions related to AMP cap removal, Medicare Part D redesign, exclusivity periods, vial wastage, drug price transparency, add-on payment and pay-fors; H.R. 5376, Build Back Better Act (reconciliation package) - provisions related to prescription drug prices; H.R. 7667, Food and Drug Amendments of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA); S. 4348, FDASLA Act of 2022 - provisions related to the reauthorization of Prescription Drug User Fee Act (PDUFA) and the Biosimilars User Fee Amendments (BsUFA); H.R. 5416, Give Kids a Chance Act - provisions related to establishing additional authorities of the FDA regarding the conduct of pediatric investigations of molecularly targeted drugs to treat cancer, and for other purposes; H.R. 6584, DEPICT Act - provisions related to amending certain FDA regulations to increase clinical trial diversity; H.R. 5585, Advanced Research Project Agency-Health Act - provisions related to the establishment of the Advanced Research Projects Agency-Health to accelerate innovation in health and medicine by investing in high-risk, high-reward research projects; H.R. 6963, Accelerated Approval Integrity Act of 2022 - provisions related to strengthening requirements for post approval studies for drugs approved using accelerated approval; S. 3799, PREVENT Pandemics Act - provisions related to pandemic readiness; S. 3700, Affordable Insulin Now Act; Discussions on Customs Border Protection changes impacting southern border plasma collections; Discussions to establish a Congressional Plasma Caucus; Discussions related to Cancer Moonshot Initiatives; S. 4293, Pharmacy Benefit Manager Transparency Act of 2022; S. 2164, Lower Costs, More Cures Act of 2021; H.R. 6833, Affordable Insulin Now Act; S. 2199, Insulin Price Reduction Act;

Client expense: $1,210,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Issues related to drug pricing, reimbursement for prescription drugs, and the pharmaceutical supply chain; Issues related to capping out of pocket costs; H.R. 6833/S. 3700 - Affordable Insulin Now Act; S.2199 - Insulin Price Reduction Act; S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; H.R. 7667 - Food and Drug Amendments of 2022.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to drug pricing, reimbursement for prescription drugs, and the pharmaceutical supply chain; H.R. 6833/S. 3700 - Affordable Insulin Now Act; S.2199 - Insulin Price Reduction Act; S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022; H.R. 7667 - Food and Drug Amendments of 2022; Issues related to the deployment of COVID treatments.

Client expense: Not reported · Firm income: $50,000

Government targets: Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, SENATE

Issues related to Affordable Care Act Premium Tax credits; H.R. 6833/S. 3700 - Affordable Insulin Now Act; S. 2199 - Insulin Price Reduction Act.

Client expense: Not reported · Firm income: $30,000

Government targets: SENATE

Issues related to drug pricing; issues related to Drug Pricing in H.R.5376 "Build Back Better Act"; issues related to influenza vaccines; issues related to RSV Access; issues related to routine immunization rates; general issues related to vaccines; issues related to 340B; issues related to funding for Pandemic influenza funding; issues related to RX to OTC switch; issues related Counterfeits in S.936 "INFORM Consumers Act"; issues related to Counterfeits in S.1843 "SHOP SAFE Act"; issues related to Pandemic Preparedness; issues related to Reconciliation; issues related to "Give Kids a Chance Act" in RACE 2.0; general issues related to HR 5376 "Build Back Better Act"; issues related to Cosmetic Reform; issues related to S.3700 and HR 6833 "Affordable Insulin Now Act"; issues related to s.2199 "Insulin Price Reduction Act"; issues related to NSURE Rule; issues related to Prescription Drug User Fee Act Reauthorization (PDUFA); issues related to COVID Vaccine Development; issues related to Clinical Trial Diversity; issues related to HR 19 "Lower Costs, More Cures Act of 2021; issues related to Accelerated Approval; issues related to HR 5416 "Give Kids a Chance Act"; issues related to HR 6972 "Give Kids a Chance Act of 2022"; issues related to HR 6854 "Depict Act"; issues related to Out-of-Pocket Cap; and general issues related to Insulin pricing.

Client expense: $1,870,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to drug pricing and reimbursement for prescription drugs; Issues related to the American Families Plan; S. Con Res 14; S. 2199 - the Insulin Price Reduction Act (116th Congress); S. 596/H.R. 1577 - Treat and Reduce Obesity Act of 2021; H.R. 5260 - Reduced Costs and Continued Cures Act.

Client expense: Not reported · Firm income: $60,000

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE

H.R. 1840/S. 814, the Expanding Access to Diabetes Self-Management Training (DSMT) Act. The Association supports this legislation to reduce barriers and increase the utilization of DSMT, which is a covered benefit under Medicare. (Lobbyists Used: Meghan Riley, Robert Goldsmith) S. 2199/H.R. 4906, The Insulin Price Reduction Act. The ADA supports this legislation which encourages lower insulin prices. (Lobbyists used: Meghan Riley, Rob Goldsmith) H.R. 2279, the Safe Step Act. The ADA supports this legislation which would require group health plans to provide an exceptions process for any medication step therapy protocol. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 4457, the Chronic Copay Elimination Act. The ADA supports this legislation which will require private health plans to cover preventive services, including screenings and certain medications, with no cost-sharing for people with chronic conditions such as diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 3, the Lower Drug Costs Now Act. This bill would require the HHS Secretary to negotiate prices for certain drugs including insulin. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 2543, the Prescription Drug Pricing Reduction Act. This bill aims to lower the cost of prescription drugs in the Medicare and Medicaid programs and to improve drug pricing transparency. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 3544, Coronavirus Relief for Seniors and People with Disabilities Act: The ADA supports this legislation which would address critical health and economic needs for older adults, people with disabilities, front-line workers and family caregivers. (Lobbyists used: Rob Goldsmith, Meghan Riley) Issues worked on not yet reflected in legislation: Protecting and strengthening the Affordable Care Act (ACA). The Association supports continued efforts to strengthen and improve the ACA which ensures access to affordable health coverage for people with diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) Medicare Diabetes Prevention Program. The Association supports efforts to make CDC-recognized virtual diabetes prevention program (DPP) providers eligible for reimbursement in MDPP. (Lobbyists used: Rob Goldsmith, Meghan Riley) Child Nutrition Reauthorization. The Association supports protecting many programs (Summer Meals, School Breakfast Program, WIC) that are a part of the Healthy and Hunger-Free Kids Act, which was last reauthorized in 2010. (Lobbyists used: Deema Tarazi, Meghan Riley)

Client expense: $120,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

H.R. 1840/S. 814, the Expanding Access to Diabetes Self-Management Training (DSMT) Act. The Association supports this legislation to reduce barriers and increase the utilization of DSMT, which is a covered benefit under Medicare. (Lobbyists Used: Meghan Riley, Robert Goldsmith) S. 2199/H.R. 4906, The Insulin Price Reduction Act. The ADA supports this legislation which encourages lower insulin prices. (Lobbyists used: Meghan Riley, Rob Goldsmith) H.R. 2279, the Safe Step Act. The ADA supports this legislation which would require group health plans to provide an exceptions process for any medication step therapy protocol. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 4457, the Chronic Copay Elimination Act. The ADA supports this legislation which will require private health plans to cover preventive services, including screenings and certain medications, with no cost-sharing for people with chronic conditions such as diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 3, the Lower Drug Costs Now Act. This bill would require the HHS Secretary to negotiate prices for certain drugs including insulin. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 2543, the Prescription Drug Pricing Reduction Act. This bill aims to lower the cost of prescription drugs in the Medicare and Medicaid programs and to improve drug pricing transparency. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 3544, Coronavirus Relief for Seniors and People with Disabilities Act: The ADA supports this legislation which would address critical health and economic needs for older adults, people with disabilities, front-line workers and family caregivers. (Lobbyists used: Rob Goldsmith, Meghan Riley) Issues worked on not yet reflected in legislation: Protecting and strengthening the Affordable Care Act (ACA). The Association supports continued efforts to strengthen and improve the ACA which ensures access to affordable health coverage for people with diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) Medicare Diabetes Prevention Program. The Association supports efforts to make CDC-recognized virtual diabetes prevention program (DPP) providers eligible for reimbursement in MDPP. (Lobbyists used: Rob Goldsmith, Meghan Riley) Child Nutrition Reauthorization. The Association supports protecting many programs (Summer Meals, School Breakfast Program, WIC) that are a part of the Healthy and Hunger-Free Kids Act, which was last reauthorized in 2010. (Lobbyists used: Deema Tarazi, Meghan Riley)

Client expense: $120,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

H.R. 1840/S. 814, the Expanding Access to Diabetes Self-Management Training (DSMT) Act. The Association supports this legislation to reduce barriers and increase the utilization of DSMT, which is a covered benefit under Medicare. (Lobbyists Used: Meghan Riley, Robert Goldsmith) S. 2199/H.R. 4906, The Insulin Price Reduction Act. The ADA supports this legislation which encourages lower insulin prices. (Lobbyists used: Meghan Riley, Rob Goldsmith) H.R. 2279, the Safe Step Act. The ADA supports this legislation which would require group health plans to provide an exceptions process for any medication step therapy protocol. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 4457, the Chronic Copay Elimination Act. The ADA supports this legislation which will require private health plans to cover preventive services, including screenings and certain medications, with no cost-sharing for people with chronic conditions such as diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 3, the Lower Drug Costs Now Act. This bill would require the HHS Secretary to negotiate prices for certain drugs including insulin. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 2543, the Prescription Drug Pricing Reduction Act. This bill aims to lower the cost of prescription drugs in the Medicare and Medicaid programs and to improve drug pricing transparency. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 3544, Coronavirus Relief for Seniors and People with Disabilities Act: The ADA supports this legislation which would address critical health and economic needs for older adults, people with disabilities, front-line workers and family caregivers. (Lobbyists used: Rob Goldsmith, Meghan Riley) Issues worked on not yet reflected in legislation: Protecting and strengthening the Affordable Care Act (ACA). The Association supports continued efforts to strengthen and improve the ACA which ensures access to affordable health coverage for people with diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) Medicare Diabetes Prevention Program. The Association supports efforts to make CDC-recognized virtual diabetes prevention program (DPP) providers eligible for reimbursement in MDPP. (Lobbyists used: Rob Goldsmith, Meghan Riley) Child Nutrition Reauthorization. The Association supports protecting many programs (Summer Meals, School Breakfast Program, WIC) that are a part of the Healthy and Hunger-Free Kids Act, which was last reauthorized in 2010. (Lobbyists used: Deema Tarazi, Meghan Riley)

Client expense: $80,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

S. 2199/H.R. 4906, The Insulin Price Reduction Act. The ADA supports this legislation which encourages lower insulin prices. (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) S.4315/H.R. 6666, COVID-19 Testing, Reaching, And Contacting Everyone (TRACE) Act. A bill that provides $100 billion in targeted COVID-19 testing funds to medically underserved communities. (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) H.R. 7062, Affordable Insulin for the COVID-19 Emergency Act. A bill that eliminates copays for insulin in Medicare Part D during the COVID-19 national emergency period. (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) S.4709, Promoting Responsible and Effective Virtual Experiences through Novel Technology to Deliver Improved Access and Better Engagement with Tested and Evidence-Based Strategies (PREVENT DIABETES) Act (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) H.R.8200, Ending Health Disparities during COVID-19 Act (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) H.R.4550, Minority Diabetes Initiative Act (Lobbyists used: Peter Goelz) H.R.133, Consolidated Appropriations Act (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott)

Client expense: $100,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 S. 3937 - Special Diabetes Program for Indians Reauthorization Act of 2020 H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act) S. 2543 - The Prescription Drug Pricing Reduction Act of 2019 S. 2199, H.R. 4906 - Insulin Price Reduction Act S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 H.R. 5749 - Affordable Insulin for All Act S. 2855, H.R. 5691 - Insulin Affordability Data Collection Act H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019 Issues and legislation related to drug pricing, specifically as it relates to insulin. Issues and legislation related to a passthrough of any/all savings to beneficiaries using insulin in Medicare Part D. Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs. Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions. Issues related to providing (during the COVID-19 emergency period) and preserving (after the COVID-19 emergency period) telehealth/telemedicine flexibilities for individuals with type 1 diabetes. S. 4315/H.R. 6666 - COVID-19 Testing, Reaching, And Contacting Everyone Act (TRACE) Act H.R. 3630 - No Surprises Act

Client expense: $60,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medication affordability and access; general diabetes prevention; S 1948/HR 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S 3129 Lower Costs, More Cures Act. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D. COVID-19 relief proposals. H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260.

Client expense: Not reported · Firm income: $70,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE, White House Office

Medication affordability and access; general diabetes prevention; S 1948/HR 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S 3129 Lower Costs, More Cures Act

Client expense: $990,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE

Medication affordability and access; general diabetes prevention; S. 1948/H.R. 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S. 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S. 3129 Lower Costs, More Cures Act; H.R. 133 Consolidated Appropriations Act, 2021

Client expense: Not reported · Firm income: $60,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE

S.2199/H.R.4906 Insulin Price Reduction Act support, Special Diabetes Program (extension to 2024)

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 S. 3937 - Special Diabetes Program for Indians Reauthorization Act of 2020 H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act) S. 2543 - The Prescription Drug Pricing Reduction Act of 2019 S. 2199, H.R. 4906 - Insulin Price Reduction Act S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 H.R. 5749 - Affordable Insulin for All Act S. 2855, H.R. 5691 - Insulin Affordability Data Collection Act H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019 Issues and legislation related to drug pricing, specifically as it relates to insulin. Issues and legislation related to a passthrough of any/all savings to beneficiaries using insulin in Medicare Part D. Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs. Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions. H.R. 5254 - Diabetic Vision Loss and Blindness Prevention Act of 2019 Issues related to providing (during the COVID-19 emergency period) and preserving (after the COVID-19 emergency period) telehealth/telemedicine flexibilities for individuals with type 1 diabetes. S. 4315/H.R. 6666 - COVID-19 Testing, Reaching, And Contacting Everyone Act (TRACE) Act

Client expense: $70,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medication affordability and access; general diabetes prevention; S 1948/HR 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S 3129 Lower Costs, More Cures Act

Client expense: $330,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE

Medication affordability and access; general diabetes prevention; S 1948/HR 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S 3129 Lower Costs, More Cures Act. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D. COVID-19 relief proposals.

Client expense: Not reported · Firm income: $70,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE, White House Office

S. 2199/H.R. 4906, The Insulin Price Reduction Act. The ADA supports this legislation which encourages lower insulin prices. (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) S.4315/H.R. 6666, COVID-19 Testing, Reaching, And Contacting Everyone (TRACE) Act. A bill that provides $100 billion in targeted COVID-19 testing funds to medically underserved communities. (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) H.R. 7062, Affordable Insulin for the COVID-19 Emergency Act. A bill that eliminates copays for insulin in Medicare Part D during the COVID-19 national emergency period. (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) S.4709, Promoting Responsible and Effective Virtual Experiences through Novel Technology to Deliver Improved Access and Better Engagement with Tested and Evidence-Based Strategies (PREVENT DIABETES) Act (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) H.R.8200, Ending Health Disparities during COVID-19 Act (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) H.R.6800, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) H.R.8406, Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) S4318, S4317, S4319, S4320, S4321, S4322, S4323, S432, Health, Economic Assistance, Liability Protection and Schools (HEALS) Act (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) S.4775, Delivering Immediate Relief to America's Families, Schools and Small Businesses Act (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) H.R. 4932/S.S.2741, Creating Opportunities Now for Necessary and Effective Care Technologies (CONNECT) for Health Act (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) Issues worked on not yet reflected in legislation: The Associations Health Equity Now initiative. The Association supports equitable access to a cure for diabetes through research, high-quality health care, diabetes drugs and management tools, healthy food and strong communities. (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) Protecting and strengthening the Affordable Care Act (ACA). The Association supports continued efforts to strengthen and improve the ACA which ensures access to affordable health coverage for people with diabetes. (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott)

Client expense: $90,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE

Medication affordability and access; general diabetes prevention; S. 1948/H.R. 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S. 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S. 3129 Lower Costs, More Cures Act

Client expense: Not reported · Firm income: $60,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE

S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 S. 3937 - Special Diabetes Program for Indians Reauthorization Act of 2020 H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act) S. 2543 - The Prescription Drug Pricing Reduction Act of 2019 S. 2199, H.R. 4906 - Insulin Price Reduction Act S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 H.R. 5749 - Affordable Insulin for All Act S. 2855, H.R. 5691 - Insulin Affordability Data Collection Act H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019 Issues and legislation related to drug pricing, specifically as it relates to insulin. Issues and legislation related to a passthrough of any/all savings to beneficiaries using insulin in Medicare Part D. Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs. Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions. H.R. 5254 - Diabetic Vision Loss and Blindness Prevention Act of 2019 Issues related to providing (during the COVID-19 emergency period) and preserving (after the COVID-19 emergency period) telehealth/telemedicine flexibilities for individuals with type 1 diabetes. Issues related to hospital inpatient blood glucose monitoring.

Client expense: $110,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medication affordability and access; general diabetes prevention; S 1948/HR 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S 3129 Lower Costs, More Cures Act

Client expense: $650,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE

Medication affordability and access; general diabetes prevention; S 1948/HR 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S 3129 Lower Costs, More Cures Act

Client expense: Not reported · Firm income: $60,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE

H.R. 1840/S. 814, the Expanding Access to Diabetes Self-Management Training (DSMT) Act. The Association supports this legislation to reduce barriers and increase the utilization of DSMT, which is a covered benefit under Medicare. (Lobbyists Used: Meghan Riley, Robert Goldsmith) S. 2199/H.R. 4906, The Insulin Price Reduction Act. The ADA supports this legislation which encourages lower insulin prices. (Lobbyists used: Meghan Riley, Rob Goldsmith) H.R. 2279, the Safe Step Act. The ADA supports this legislation which would require group health plans to provide an exceptions process for any medication step therapy protocol. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 4457, the Chronic Copay Elimination Act. The ADA supports this legislation which will require private health plans to cover preventive services, including screenings and certain medications, with no cost-sharing for people with chronic conditions such as diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 3, the Lower Drug Costs Now Act. This bill would require the HHS Secretary to negotiate prices for certain drugs including insulin. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 2543, the Prescription Drug Pricing Reduction Act. This bill aims to lower the cost of prescription drugs in the Medicare and Medicaid programs and to improve drug pricing transparency. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 3544, Coronavirus Relief for Seniors and People with Disabilities Act: The ADA supports this legislation which would address critical health and economic needs for older adults, people with disabilities, front-line workers and family caregivers. (Lobbyists used: Rob Goldsmith, Meghan Riley) H.R. 6666, COVID-19 Testing, Reaching, And Contacting Everyone (TRACE) Act. A bill that provides $100 billion in targeted COVID-19 testing funds to medically underserved communities. (Lobbyists used: Elise Tollefson, Peter Goelz) H.R. 7062, Affordable Insulin for the COVID-19 Emergency Act. A bill that eliminates copays for insulin in Medicare Part D during the COVID-19 national emergency period. (Lobbyists used: Elise Tollefson, Peter Goelz, Matt Scott) Issues worked on not yet reflected in legislation: Protecting and strengthening the Affordable Care Act (ACA). The Association supports continued efforts to strengthen and improve the ACA which ensures access to affordable health coverage for people with diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) Medicare Diabetes Prevention Program. The Association supports efforts to make CDC-recognized virtual diabetes prevention program (DPP) providers eligible for reimbursement in MDPP. (Lobbyists used: Rob Goldsmith, Meghan Riley) Child Nutrition Reauthorization. The Association supports protecting many programs (Summer Meals, School Breakfast Program, WIC) that are a part of the Healthy and Hunger-Free Kids Act, which was last reauthorized in 2010. (Lobbyists used: Deema Tarazi, Meghan Riley)

Client expense: $120,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

H.R. 1840/S. 814, the Expanding Access to Diabetes Self-Management Training (DSMT) Act. The Association supports this legislation to reduce barriers and increase the utilization of DSMT, which is a covered benefit under Medicare. (Lobbyists Used: Meghan Riley, Robert Goldsmith) S. 2199/H.R. 4906, The Insulin Price Reduction Act. The ADA supports this legislation which encourages lower insulin prices. (Lobbyists used: Meghan Riley, Rob Goldsmith) H.R. 2279, the Safe Step Act. The ADA supports this legislation which would require group health plans to provide an exceptions process for any medication step therapy protocol. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 4457, the Chronic Copay Elimination Act. The ADA supports this legislation which will require private health plans to cover preventive services, including screenings and certain medications, with no cost-sharing for people with chronic conditions such as diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 3, the Lower Drug Costs Now Act. This bill would require the HHS Secretary to negotiate prices for certain drugs including insulin. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 2543, the Prescription Drug Pricing Reduction Act. This bill aims to lower the cost of prescription drugs in the Medicare and Medicaid programs and to improve drug pricing transparency. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 3544, Coronavirus Relief for Seniors and People with Disabilities Act: The ADA supports this legislation which would address critical health and economic needs for older adults, people with disabilities, front-line workers and family caregivers. (Lobbyists used: Rob Goldsmith, Meghan Riley) Issues worked on not yet reflected in legislation: Protecting and strengthening the Affordable Care Act (ACA). The Association supports continued efforts to strengthen and improve the ACA which ensures access to affordable health coverage for people with diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) Medicare Diabetes Prevention Program. The Association supports efforts to make CDC-recognized virtual diabetes prevention program (DPP) providers eligible for reimbursement in MDPP. (Lobbyists used: Rob Goldsmith, Meghan Riley) Child Nutrition Reauthorization. The Association supports protecting many programs (Summer Meals, School Breakfast Program, WIC) that are a part of the Healthy and Hunger-Free Kids Act, which was last reauthorized in 2010. (Lobbyists used: Deema Tarazi, Meghan Riley)

Client expense: $120,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201 - Families First Coronavirus Response Act S. 3548 - CARES Act H.R. 6800 - The Heroes Act Medication affordability and access; general diabetes prevention; S. 1948/H.R. 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S. 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S 3129 Lower Costs, More Cures Act

Client expense: Not reported · Firm income: $60,000

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE

H.R. 1530/S. 595 Treat and Reduce Obesity Act; Medicare Diabetes Prevention Program; Issues related to Medicare Part D; Issues related to International Pricing Index (IPI)/reference pricing in Medicare; H.R. 107 - related to maximum Medicaid rebates; Medicare Part D Rebate Rule; H.R.3 Lower Drug Costs Now Act of 2019; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019; H.R. 4906/S. 2199, Insulin Price Reduction Act.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 1503 - Orange Book Transparency Act of 2019; Issues related to drug importation in general; H.R. 4906/S. 2199, Insulin Price Reduction Act; S. 1895, Lower Health Care Costs Act;

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 1840/S. 814, the Expanding Access to Diabetes Self-Management Training (DSMT) Act. The Association supports this legislation to reduce barriers and increase the utilization of DSMT, which is a covered benefit under Medicare. (Lobbyists Used: Meghan Riley, Robert Goldsmith) S. 2199/H.R. 4906, The Insulin Price Reduction Act. The ADA supports this legislation which encourages lower insulin prices. (Lobbyists used: Meghan Riley, Rob Goldsmith) H.R. 2279, the Safe Step Act. The ADA supports this legislation which would require group health plans to provide an exceptions process for any medication step therapy protocol. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 4457, the Chronic Copay Elimination Act. The ADA supports this legislation which will require private health plans to cover preventive services, including screenings and certain medications, with no cost-sharing for people with chronic conditions such as diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 3, the Lower Drug Costs Now Act. This bill would require the HHS Secretary to negotiate prices for certain drugs including insulin. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 2543, the Prescription Drug Pricing Reduction Act. This bill aims to lower the cost of prescription drugs in the Medicare and Medicaid programs and to improve drug pricing transparency. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 3544, Coronavirus Relief for Seniors and People with Disabilities Act: The ADA supports this legislation which would address critical health and economic needs for older adults, people with disabilities, front-line workers and family caregivers. (Lobbyists used: Rob Goldsmith, Meghan Riley) Issues worked on not yet reflected in legislation: Protecting and strengthening the Affordable Care Act (ACA). The Association supports continued efforts to strengthen and improve the ACA which ensures access to affordable health coverage for people with diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) Medicare Diabetes Prevention Program. The Association supports efforts to make CDC-recognized virtual diabetes prevention program (DPP) providers eligible for reimbursement in MDPP. (Lobbyists used: Rob Goldsmith, Meghan Riley) Child Nutrition Reauthorization. The Association supports protecting many programs (Summer Meals, School Breakfast Program, WIC) that are a part of the Healthy and Hunger-Free Kids Act, which was last reauthorized in 2010. (Lobbyists used: Deema Tarazi, Meghan Riley)

Client expense: $80,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE

Medication affordability and access; general diabetes prevention; S. 1948/H.R. 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S. 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S. 3129 Lower Costs, More Cures Act.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Medication affordability and access; general diabetes prevention; S 1948/HR 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S 3129 Lower Costs, More Cures Act

Client expense: $610,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE

S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act) H.R. 965 - CREATES Act of 2019 S. 2543 - The Prescription Drug Pricing Reduction Act of 2019 S. 2199, H.R. 4906 - Insulin Price Reduction Act S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 S. 2855 - Insulin Affordability Data Collection Act H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019 Issues and legislation related to drug pricing, specifically as it relates to insulin Issues and legislation related to a passthrough of any/all savings to beneficiaries using insulin in Medicare Part D. Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions. H.R. 5254 - Diabetic Vision Loss and Blindness Prevention Act of 2019 Issues relates to expanding telehealth under Medicare for the purposes of qualifying visits for insulin pumps and continuous glucose monitors. S. 3548, H.R. 748 - CARES Act

Client expense: $190,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R. 6201 - Families First Coronavirus Response Act S. 3548 - CARES Act Medication affordability and access; general diabetes prevention; S. 1948/H.R. 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S. 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S 3129 Lower Costs, More Cures Act

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE

Medication affordability and access; general diabetes prevention; S 1948/HR 3709 Chronic Disease Management Act and general issues related to High Deductible Health Plan pre-deductible coverage of treatments and services for chronic diseases; implementation of P.L. 115-80 (H.R. 309/S. 920) Clinical Care Commission Act; S 2199/H.R. 4906 Insulin Price Reduction Act; H.R. 3 Elijah Cummings Lower Drug Costs Now Act; S. 1895 Lower Health Care Costs Act; H.R. 19/S 3129 Lower Costs, More Cures Act

Client expense: $920,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 447: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation H.R. 478: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation H.R. 965: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 985: FAST Generics Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems H.R. 1093: Stop Price Gouging Act - Provisions related to prescription drug pricing H.R. 1478: Affordable Insulin Act of 2019 - Provisions related to importation H.R. 1506: Fair and Immediate Release (FAIR) of Generic Drugs Act - Provisions related to generic prescription drug approvals H.R. 1922: Restoring Access to Medication Act of 2019 - Provisions related to prescription drug access H.R. 2064: To amend title XI of the Social Security Act to require manufacturers of certain drugs, devices, biologicals, and medical supplies to report on product samples provided to certain health care providers, and for other purposes - Provisions related to prescription drug samples H.R. 2069: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs H.R. 2087: Drug Price Transparency Act - Provisions related to prescription drug pricing and transparency H.R. 2113: Prescription Drug STAR Act - Provisions related to prescription drug pricing, reporting and product samples H.R. 2296: FAIR Drug Pricing Act of 2019 / More Efficient Tools to Realize Information for Consumers Act - Provisions related to prescription drug pricing and transparency H.R. 2376: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 2569: Comprehensive Addiction Resources Emergency Act of 2019 - Provisions related to opioid crisis response funding H.R. 2732: Lessening Addiction By Enhancing Labeling Opioids Act of 2019 - Provisions related to labeling of prescription drugs H.R. 2734: Safer Prescribing of Controlled Substances Act - Provisions related to the prescribing of prescription drugs H.R. 2917: Opioid Crisis Accountability Act of 2019 - Provisions related to prescription drug marketing H.R. 3223: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers H.R. 3327: Drug Price Transparency for Medicare Patients Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising H.R. 3415: Real-Time Beneficiary Drug Cost Bill - Provisions related to drug pricing transparency H.R. 3947: Competition Prescription Act of 2019 - Provisions related to prescription drug pricing, patents, and other provisions H.R. 4010: Emergency Access to Insulin Act of 2019 - Provisions related to prescription drug access programs H.R. 4106: Responsibility in Drug Advertising Act of 2019 - Provisions related to direct-to-consumer prescription drug advertising H.R. 4158: CURE High Drug Prices Act - Provisions related to prescription drug pricing and transparency H.R. 4439: Creating Hope Reauthorization Act - Provisions related to rare disease priority review vouchers H.R. 4538: Closing Loopholes for Orphan Drugs Act - Provisions related to 340B prescription drug exclusions H.R. 4633: Investing in Safety and Innovation Act of 2019 - Provisions related to FDA programs reauthorization H.R. 4640: Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2019 - Provisions related to prescription drug pricing and negotiation H.R. 4667: Biomedical Innovation Expansion Act of 2019 - Provisions related to NIH programs reauthorization H.R. 4710: Pharmaceutical Independence Long-Term Readiness Reform Act - Provisions related to the supply chain H.R. 4711: No Tax Breaks for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising H.R. 4812: Ensuring Compliance Against Drug Diversion Act of 2019 - Provisions related to registrations under the Controlled Substances Act H.R. 4814: Suspicious Order Identification Act of 2019 - Provisions related to reporting on distribution of controlled substances H.R. 4906: Insulin Price Reduction Act - Provisions related to prescription drug pricing and transparency H.R. 4963: Stop the Importation and Manufacturing of Synthetic Analogues Act of 2019 - Provisions related to synthetic analogues H.R. 5031: Medical Innovation Act of 2019 - Provisions related to prescription drug manufacturer taxation and supplemental fees H.R. 5198: Patients' Right to Know Their Medication Act of 2019 - Provisions related to prescription drug labeling H.R. 5239: Prescription Drug Price Reporting Act - Provisions related to prescription drug pricing transparency H.R. 5304: PBM Transparency in Prescription Drug Costs Act - Provisions related to prescription drug pricing transparency H.R. 5381: International Pharmaceutical Transparency Act of 2019 - Provisions related to prescription drug labeling H.R. 5382: To create a mechanism whereby insulin manufacturers may sell directly to consumers at current net prices - Provisions related to prescription drug pricing H.R. 5442: To amend title XXVII of the Public Health Service Act and title XVIII of the Social Security Act to require pharmacies to disclose any differential between the cost of a prescription drug based on whether certain individuals use prescription drug coverage to acquire such drug, and for other purposes - Provisions related to prescription drug pricing and transparency H.R. 5497: Conditional Approval Act - Provisions related to approval pathway S. 61: Safe and Affordable Drugs from Canada Act of 2019 - Provisions related to importation S. 73: End Taxpayer Subsidies for Drug Ads Act - Provisions related to direct-to-consumer prescription drug advertising S. 97: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation S. 340: Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019 - Provisions related to Risk Evaluation and Mitigation Strategies (REMS) and limited distribution systems S. 378: Stop Price Gouging Act - Provisions related to prescription drug pricing S. 474: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019 - Provisions related to increases in the wholesale acquisition costs of prescription drugs S. 637: Combatting Unreasonable Rises and Excessively (CURE) High Drug Prices Act - Provisions related to prescription drug pricing and transparency S. 657: Drug Price Transparency Act - Provisions related to prescription drug pricing transparency and commercial market rebates S. 660: Efficiency and Transparency in Petitions Act - Provisions related to the FDA citizen petition process S. 1140: Protecting Access to Biosimilars Act of 2019 - Provisions related to biological products S. 1227: Prescription Pricing for the People Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 1250: American Cures Act - Provisions related to pharmaceutical research and development S. 1391: FAIR Drug Pricing Act of 2019 - Provisions related to prescription drug pricing and transparency S. 1437: Drug-price Transparency in Communications (DTC) Act - Provisions related to direct-to-consumer prescription drug advertising S. 1532: Pharmacy Benefit Manager Accountability Study Act of 2019 - Provisions related to prescription drug pricing transparency and pharmacy benefit managers S. 2004: Emergency Access to Insulin Act of 2019 - Provisions related to prescription drug pricing S. 2103: Affordable Insulin Approvals Now Act - Provisions related to FDA prescription drug approvals S. 2161: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2019 - Provisions related to reciprocity S. 2199: Insulin Price Reduction Act - Provisions related to prescription drug pricing and transparency S. 2723: Mitigating Emergency Drug Shortages Act - Provisions related to prescription drug pricing transparency and other provisions S. 2897: Patient-Centered Outcomes Research Institute Reauthorization Act - Provisions related to PCORI reauthorization Transparency policy issues Drug cost and pricing policy issues Drug importation and counterfeiting policy issues HHS Safe Importation Action Plan Prescription drug take back and secure disposal policy issues Policy issues related to prescription drug abuse and opioids Expanded access policy issues Generic drug approval process policy issues High deductible health plans/HSA policy issues Sharing of truthful and non-misleading information about medicines with healthcare professionals and payors Risk Evaluation and Mitigation Strategy (REMS) policy issues FDA modernization policy issues PDUFA implementation policy issues 340B drug discount program policy issues Bipartisan Budget Act of 2018 (Public Law 115-123) - Part D provisions Patient assistance program policy issues Foreign manufacturing policy issues Biosimilar approval and reimbursement policy issues Drug compounding policy issues including federal oversight of compounded drugs Cancer drug vial size policy issues TRICARE pharmacy pilot program Drug shortages policy issues Request for Information: HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs (RIN 0991-ZA49) Proposed Rule; Importation of Prescription Drugs (RIN 0910-AI45)

Client expense: $6,450,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)

H.R. 1530/S. 595 Treat and Reduce Obesity Act; Medicare Diabetes Prevention Program; Issues related to Medicare Part D; Issues related to International Pricing Index (IPI)/reference pricing in Medicare; H.R. 107 - related to maximum Medicaid rebates; Medicare Part D Rebate Rule; H.R.3 Lower Drug Costs Now Act of 2019; H.R. 19, Lower Costs, More Cures Act of 2019; S. 2543, Prescription Drug Pricing Reduction Act of 2019; H.R. 4906/S. 2199, Insulin Price Reduction Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

H.R. 1520 - Purple Book Continuity Act of 2019; H.R. 1503 - Orange Book Transparency Act of 2019; Issues related to importation; H.R. 4906/S. 2199, Insulin Price Reduction Act; S. 1895, Lower Health Care Costs Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S. 1895 - Lower Health Care Costs Act H.R. 2668 - Special Diabetes Program Reauthorization Act of 2019 H.R. 2680 - Special Diabetes Program for Indians Reauthorization Act of 2019 H.R. 2328 - Reauthorizing and Extending Americas Community Health Act (REACH Act) H.R. 965 - CREATES Act of 2019 S. 2543 - The Prescription Drug Pricing Reduction Act of 2019 S. 2199, H.R. 4906 - Insulin Price Reduction Act S. 2004, H.R. 4010 -- Emergency Access to Insulin Act of 2019 H.R. 3 - Lower Drug Costs Now Act of 2019 S. 2855 - Insulin Affordability Data Collection Act H.R. 19, S. 3129 - Lower Costs, More Cures Act of 2019 Issues and legislation related to drug pricing, specifically as it relates to insulin Issues and legislation related to providing flexibility in the split of a deductible between devices and prescription drugs Issues related to the importance of preserving health insurance protections for individuals with pre-existing conditions. H.R. 5254 - Diabetic Vision Loss and Blindness Prevention Act of 2019

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 965/S. 340: The Creating and Restoring Equal Access to Equivalent Samples (CREATES Act). Implementation of the e-prescribing provisions of the controlled substances provisions of the SUPPORT Act (P.L. 115-271). S. 1895: The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs. S. 2199: The Insulin Price Reduction Act, requires private health insurance plans and Medicare Part D plans to eliminate rebates for insulin and limit out of pocket costs. H.R. 3: Elijah E. Cummings Lower Drugs Costs Now Act, provisions to modernize the Part D benefit and provisions that require HHS to negotiate prices for certain drugs. H.R. 19/S. 3129: The Lower Costs, More Cures Act, reforms drug pricing by promoting greater competition and redesigns the Medicare Part D drug benefit. S. 3013: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act, provisions allowing for the offering of additional prescription drug plans under Medicare Part D. S. 2543: The Prescription Drug Pricing Reduction Act, legislation to amend Medicare and Medicaid to lower prescription drug prices and strengthen safeguards related to prescription drug. Provisions related to inflation protection and PBM transparency. Medicare Advantage and Part D Drug Pricing Final Rule, (CMS-4180-F), provisions related to pharmacy Direct and Indirect Negotiation and a real-time benefit tool. Outreach and education on pharmacy DIR in Medicare Part D. H.R. 2115: Public Disclosure of Drug Discounts and Real-time Beneficiary Drugs Costs Act, provisions requiring HHS to publish information online about discounts under Medicare Advantage and Part D and requirements related to real-time benefits tool implementation. H.R. 1791: The Payment Commission Data Act of 2019, legislation that would require government commission to receive rebate and other data from PBMs/Part D plans.

Client expense: $140,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1840/S. 814, the Expanding Access to Diabetes Self-Management Training (DSMT) Act. The Association supports this legislation to reduce barriers and increase the utilization of DSMT, which is a covered benefit under Medicare. (Lobbyists Used: Meghan Riley, Robert Goldsmith, Gwen Rathbun, Deema Tarazi) S. 1895, the Lower Health Care Costs Act. Includes 5-year reauthorization of the Special Diabetes Program (SDP), a provision that would end surprise medical billing, and provisions lowering prescription drug costs, which ADA supports. (Lobbyists used: Gwen Rathbun, Robert Goldsmith, Meghan Riley, Deema Tarazi) S.2302, The Americas Transportation Infrastructure Act. Support including provisions for transportation alternative programs, which were included in S.1098 and safe routes to school. (Lobbyist used: Deema Tarazi, Meghan Riley) S.2358, The Wise Investment in Children Act of 2019 (WIC Act). Support extending child eligibility to age six or the beginning of kindergarten; extending infant certification periods to two years; and extending postpartum womens eligibility to two years. (Lobbyist used: Deema Tarazi, Meghan Riley) S. 2199/H.R. 4906, The Insulin Price Reduction Act. The ADA supports this legislation which encourages lower insulin prices. (Lobbyists used: Meghan Riley, Rob Goldsmith) H.R. 2279, the Safe Step Act. The ADA supports this legislation which would require group health plans to provide an exceptions process for any medication step therapy protocol. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 4457, the Chronic Copay Elimination Act. The ADA supports this legislation which will require private health plans to cover preventive services, including screenings and certain medications, with no cost-sharing for people with chronic conditions such as diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) HR 3, the Lower Drug Costs Now Act. This bill would require the HHS Secretary to negotiate prices for certain drugs including insulin. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) S. 2543, the Prescription Drug Pricing Reduction Act. This bill aims to lower the cost of prescription drugs in the Medicare and Medicaid programs and to improve drug pricing transparency. The ADA has not endorsed this legislation but does support specific provisions of this bill. (Lobbyists used: Rob Goldsmith, Meghan Riley) Issues worked on not yet reflected in legislation: Improving access to affordable and adequate health care. The ADA supports continued efforts to protect and expand benefits under the Affordable Care Act (ACA), Medicare, Medicaid, and other health plans to ensure access to affordable health coverage for people with diabetes. (Lobbyists used: Meghan Riley, Rob Goldsmith) Medicare Diabetes Prevention Program. The Association supports efforts to make CDC-recognized virtual diabetes prevention program (DPP) providers eligible for reimbursement in MDPP. (Lobbyists used: Rob Goldsmith, Meghan Riley) Child Nutrition Reauthorization. The Association supports protecting many programs (Summer Meals, School Breakfast Program, WIC) that are a part of the Healthy and Hunger-Free Kids Act, which was last reauthorized in 2010. (Lobbyists used: Deema Tarazi, Meghan Riley)

Client expense: $80,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE

HR 803: Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, pharmacy payments & adjustments in Part D/ DIR. HR 789: To amend title XVIII of the Social Security Act to prohibit prescription drug plan sponsors and MA-PD organizations under the Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. HR 1035: The Prescription Drug Price Transparency Act, requires greater transparency and accountability from PBMs. HR 1034/S 640: The Phair Pricing Act, lowers the cost of prescription medication for patients in the Medicare Part D program. HR 965/S 340: "The Creating and Restoring Equal Access To Equivalent Samples (CREATES) Act." S 64: "Preserve Access to Affordable Generics and Biosimilars Act," bars pay-for-delay for generics and biosimilars. Proposals to address pay-for-delay, orphan drug abuse and patent evergreening. Implementation of the e-prescribing provisions of controlled substances provisions of the SUPPORT Act, (P.L. 115-271). The Payment Commission Data Act, H.R. 1264, H.R. 1781 and S. 801: provisions allowing MACPAC and MedPAC access to certain drug price concession and rebate information. S. 1895: The Lower Health Care Costs Act, Sec. 306 Health Plan Oversight of PBMs. Issues related to implementation of a real-time benefit tool. S. 1416: The Affordable Prescriptions for Patients Act of 2019, address product hopping and patent thickets by giving the FTC greater powers to investigate and bring legal actions. S. 1384: The Prescription Drug Rebate Reform Act, would require all patients coinsurance obligations be set as a percentage of net price, rather than list price, before or after a deductible is met. S. 1532: The Pharmacy Benefit Manager Accountability Study Act of 2019, (provisions requiring GAO to submit a report on PBMs). H.R. 2115: the "Public Disclosure of Drug Discounts Act, requires PBMs to disclose the aggregate amount of rebates, discounts, and price concessions that PBMs negotiate with drug manufacturers, and make this information publicly available to allow the public to compare the aggregate rebates, discounts, and price concessions that PBMs receive. H.R. 2113: "The Prescription Drug STAR (Sunshine, Transparency, Accountability and Reporting) Act," provisions related to disclosure of PBM-pharmaceutical company negotiated rebates. H.R. 2376/S. 1227: Prescription Pricing for the People Act of 2019," FTC study of PBMs. S.2199: The Insulin Price Reduction Act, require private health insurance plans and Medicare Part D plans to eliminate rebates for insulin and limit out of pocket costs ($250 for individuals, and $500 for families) if manufacturers reduce insulin list prices to prices during plan year 2006 and do not raise insulin prices above inflation. H.R. 3: Lower Drug Costs Now Act of 2019, Provisions to establish a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollment.

Client expense: $80,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE